[Fifteen years of use of anti-TNF antibodies in moderate to severe Crohn's disease: how to make the best of this experience].
After fifteen years of use, the anti-TNF antibodies have become the corner stone of the treatment of moderate and severe Crohn's disease. The skill acquired over the years through experimental trials and clinical experience leads to increased therapeutic efficacy and minimized risks. These antibodies are introduced increasingly earlier in Crohn's disease as well as in a broader range of patients, aiming at changing the natural history of the diseases by avoiding the development of intestinal tissue damage and complications.
Service de Gastroentérologie, CHU de Liège, Belgique. edouard.louis@ulg.ac.be
E
E
Louis
C
C
Reenaers
M A
MA
Meuwis
C
C
Van Kemseke
P
P
Latour
N
N
Chapelier
S
S
Wertz
C
C
Coïmbra
P
P
Meunier
J
J
Belaiche
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha